MoUJun 4, 2026, 08:32 AM
SOPHiA GENETICS & MSK Sign MOU for Precision Oncology Joint Venture
AI Summary
SOPHiA GENETICS announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK), signing a Memorandum of Understanding (MOU) to form a joint venture. This partnership aims to establish a precision medicine hub that will leverage MSK's clinical diagnostics innovation and extensive genomic dataset alongside SOPHiA GENETICS’s Ai platform, SOPHiA DDM™. The initiative seeks to discover, develop, and deploy a new generation of precision oncology solutions to patients worldwide, accelerating the translation of discoveries into clinical care and providing infrastructure for biopharma partners.
Key Highlights
- SOPHiA GENETICS signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK).
- The MOU aims to form a joint venture to establish a precision medicine hub for oncology.
- The hub will combine MSK's clinical data and expertise with SOPHiA GENETICS’s Ai platform, SOPHiA DDM™.
- The goal is to discover, develop, and deploy a new generation of precision oncology globally.
- SOPHiA DDM™ has analyzed over 2.5 million cases since 2014, pioneering decentralized precision oncology.
- MSK's in-house NGS program has sequenced over 150,000 tumor samples since 2014.
- The hub is expected to accelerate discoveries from bench to clinical care and expand access to MSK’s oncology intelligence.
- It will also provide dedicated infrastructure for next-generation companion diagnostics for biopharma partners.
Price Impact
More from SOPH